What is rheumatoid arthritis and how should it be managed?

Rheumatoid Arthritis: Definition and Management

Rheumatoid arthritis is a chronic autoimmune disease causing symmetric joint inflammation and destruction, requiring immediate DMARD therapy upon diagnosis with methotrexate as first-line treatment, targeting remission or low disease activity within 6 months. 1, 2

What is Rheumatoid Arthritis?

RA is a systemic autoimmune disorder affecting 0.5-0.7% of adults, with 2:1 female predominance and peak incidence at ages 55-75 years 3. The disease causes:

• Symmetric polyarthritis primarily affecting proximal interphalangeal, metacarpophalangeal, and wrist joints
• Cartilage and bone destruction leading to irreversible disability if untreated
• Extra-articular manifestations including rheumatoid nodules, vasculitis, interstitial lung disease, and cardiovascular complications
• Autoantibody production (rheumatoid factor and/or anti-citrullinated peptide antibodies present in 40-60% at diagnosis) 3

Diagnosis is clinical, based on characteristic joint swelling patterns, autoantibodies, and elevated inflammatory markers (CRP/ESR), with no formal diagnostic criteria required 3.

Core Management Principles

Overarching Treatment Philosophy

Treatment must be based on shared decision-making between patient and rheumatologist, with rheumatologists providing primary specialty care 1, 2. This is critical because:

• Patients need education about disease risks and treatment benefits/risks
• Two-way communication ensures adherence and addresses concerns (e.g., methotrexate fears from its high-dose cancer use) 2
• Multiple drug options with different mechanisms may be needed throughout life 2

Treatment Targets and Monitoring

The goal is achieving remission (ACR-EULAR criteria preferred) or low disease activity in every patient 1, 2. This target-driven approach is fundamental because:

• Remission halts structural damage and maximizes functional outcomes 1
• DAS28 <2.6 is NOT sufficiently stringent for defining remission 1
• Low disease activity is an acceptable alternative when remission is unattainable, particularly in long-standing disease 1

Monitoring frequency must be aggressive:

• Every 1-3 months during active disease 1, 2
• If no improvement by 3 months OR target not reached by 6 months → adjust therapy 1, 2
• Once stable, monitoring can extend to every 6-12 months 1

Step-by-Step Treatment Algorithm

Phase I: Initial Treatment (DMARD-Naive Patients)

Start methotrexate immediately upon diagnosis 1, 2, 4:

• Begin 7.5-10 mg orally weekly
• Escalate to 20-25 mg weekly within 4-8 weeks 3
• This is a strong recommendation with highest level of evidence 4

Add short-term low-dose glucocorticoids 1, 2:

• Prednisone 5-7.5 mg daily OR single IM methylprednisolone 80-160 mg 3
• Taper as rapidly as clinically feasible, ideally within 3-6 months 1, 2
• This combination (MTX + GC) has shown no inferiority to starting biologics in DMARD-naive patients 2

If methotrexate contraindicated or early intolerance:

• Use sulfasalazine (2-4 g/day) or leflunomide (20 mg/day) 1, 3

Critical pitfall: Approximately 40% achieve remission with first-line therapy alone within 6 months 3. Do NOT prematurely escalate to biologics without adequate MTX trial at optimal dosing.

Phase II: Inadequate Response to First Strategy

At 3 months: Assess for ANY improvement At 6 months: Target must be achieved

If target not met, decision depends on prognostic factors:

Poor prognostic factors present (high disease activity, RF/ACPA especially at high levels, early joint damage, or failure of 2 csDMARDs) 1:

• Add a biologic DMARD or JAK inhibitor 1, 2
• Biologics should be combined with methotrexate (or another csDMARD) 2
• Options include:
  • TNF inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab)
  • Abatacept
  • Tocilizumab or sarilumab (IL-6 inhibitors)
  • Rituximab (in certain circumstances: history of lymphoma or demyelinating disease) 1
  • JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib) 2, 5

Important safety consideration for JAK inhibitors: In patients ≥65 years with heavy smoking history or cardiovascular/malignancy risk factors, JAK inhibitors should be used cautiously due to increased risk of MACEs, malignancies, and thromboembolic events 6, 5. Biologics are preferred in this population.

Poor prognostic factors absent:

• Switch to another csDMARD strategy (e.g., leflunomide, sulfasalazine, or triple therapy: MTX + sulfasalazine + hydroxychloroquine) 1, 2

Special note on monotherapy: IL-6 inhibitors and JAK inhibitors have some advantages as monotherapy compared to other biologics when csDMARD comedication cannot be used 2.

Phase III: Biologic/JAK Inhibitor Failure

If first biologic or JAK inhibitor fails, switch to another agent 1, 2:

After TNF inhibitor failure:

• Can use another TNF inhibitor (cycling) OR
• Switch to different mechanism: abatacept, rituximab, IL-6 inhibitor, or JAK inhibitor 1, 2
• Evidence slightly favors switching mechanisms over cycling, though both are acceptable 6

After non-TNF biologic failure:

• Limited evidence for optimal sequencing
• Tailor based on disease characteristics, comorbidities, and drug-specific risks 6
• SELECT-CHOICE showed upadacitinib superior to abatacept after biologic failure 6

After JAK inhibitor failure:

• Can switch to biologic DMARD
• Post-hoc analysis suggests patients failing adalimumab do better switching to upadacitinib than vice versa 6

Phase IV: Sustained Remission - Tapering Strategy

Only consider tapering after sustained remission (≥6-12 months at same dose) 1, 2, 6:

Sequence of tapering:

1. First, taper and discontinue glucocorticoids (if still on them)
2. Then consider tapering biologics/JAK inhibitors (dose reduction or interval prolongation), especially if combined with csDMARD 1, 2
3. Finally, cautiously reduce csDMARD dose as shared decision with patient 1, 2

Critical warning: Complete drug discontinuation often leads to flare 5. Tapering is safer than stopping entirely.

Special Clinical Situations

Rheumatoid vasculitis: Rituximab is specifically recommended 6

Interstitial lung disease: Avoid TNF inhibitors 6

High cardiovascular/malignancy risk: Prefer biologics over JAK inhibitors 6, 5

Key Factors Beyond Disease Activity

When adjusting therapy, always consider 1:

• Progression of structural damage on imaging
• Comorbidities (cardiovascular disease, infections, malignancy history)
• Safety issues and adverse events
• Individual patient factors and preferences
• Cost considerations (medical and societal) 1, 2

Expected Outcomes

• 40% achieve remission with MTX + GC within 6 months 3
• 80% achieve remission or low disease activity with addition of biologics/JAK inhibitors 3
• Early treatment (ideally within 6 weeks of symptom onset) is crucial for preventing irreversible joint damage 3

The evidence strongly supports this algorithmic approach, with the 2014 EULAR guidelines 1 providing the framework, updated by 2019 2 and 2025 5 revisions, and corroborated by 2021 ACR guidelines 4 and recent comprehensive reviews 3.